Clovis Oncology Inc., of Boulder, Colo., reported revenue of $22.8 million from sales of its ovarian cancer treatment, Rubraca (rucaparib). The company gave away drug worth an additional $9.6 million. Net loss for the quarter was $89.9 million, or $1.71 per share. Clovis ended the quarter with $604.4 million in cash, cash equivalents and available-for-sale securities. Shares of Clovis (NASDAQ:CLVS) closed down $4.98, or 30 percent, to $11.63 on Wednesday.